Search

Your search keyword '"Shengjuan Yao"' showing total 3 results
Start Over Author "Shengjuan Yao"
3 results on '"Shengjuan Yao"'

1. One‐year status of hepatic venous pressure gradient measurement from 85 hospitals in China

Author

Jitao Wang, Ting Cui, Linpeng Zhang, Zhiping Yan, Lei Li, Jinjun Chen, Junhui Sun, Hua Xiang, He Zhu, Hao Wu, Jiancuo Gengzang, Feng Zhang, Wei Wu, Guohong Cao, Wuhua Guo, Haibin Shi, Hui Xue, Guangjun Huang, Qiang Yu, Meng Niu, Huiling Xiang, Derun Kong, Wei Gou, Xuefeng Luo, Fuliang He, Min Yuan, Wei Liu, Yong Wang, Hongjie Hu, Xiaoli Zhu, Tao Yu, Qinxue Sun, Wei Qu, Ting Lu, Deqiang Ma, Li Zhang, Jun Ma, Jun Yang, Ketao Mu, Xiaoliang Zhu, Kai Xiong, Huiguo Ding, Shengjuan Yao, Mingsheng Huang, Fang Wang, Zexin Wang, Yong Huang, Jianan Li, Hongfeng Yi, Birun Huang, Zhongwei Zhao, Duiping Feng, Yanming Lei, Changlong Hou, Wenbo Guo, Shirong Liu, Gaojun Teng, Kangshun Zhu, Fan Wu, Xiaogang Hu, Wenfeng Zhang, Shaoqi Yang, Zhouchao Hu, Pengfei Pang, Shaowu Zhuang, Weidong Wang, Qingliang Zhu, Kunpeng Zhang, Chengyu Liu, Dongliang Li, Chao Ma, Hong Jiang, Xingong Zhao, Weixin Ren, Zhiwei Wang, Lei Yu, Fuhuang Lin, Chaoguang Yan, Feng Wang, Hui Huan, Wenyong Shen, Shaofei He, Chengda Zhang, Jinlun Bao, Jiangtao Liu, Jun Wu, Jianbo Zhao, Jian Zhang, and Xiaolong Qi

Subjects
application status, hepatic vein pressure gradient, questionnaire survey, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Aims Surveys and research on the applications of the hepatic venous pressure gradient (HVPG) are important for understanding the current status and future development of this technology in China. This article aimed to investigate the status of hepatic venous pressure gradient measurement in China in 2022. Methods We investigated the overall status of HVPG technology in China—including hospital distribution, hospital level, annual number of cases, catheters used, average cost, indications, and current challenges by using online questionnaire. By counting the number and percentages of cases of these results, we hope to clarify the current status of HVPG measurements in China. Results According to the survey, 85 hospitals in China used HVPG technology in 2022 distributed across 29 provinces. A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022, of which 2813 cases (56.4%) were measured alone. The average cost of HVPG measurement was 5646.8 ± 2327.9 CNY. Of the clinical teams who performed the measurements (sometimes multiple per hospital), 94.3% (82/87) used the balloon method, and the majority of the teams (72.4%, 63/87) used embolectomy catheters. Conclusions This survey clarified the clinical application status of HVPG in China and confirmed that some medical institutions in China have established a foundation for this technology. It is still necessary to continue promoting and popularizing this technology in the future.

Published
2024
Full Text
View/download PDF

2. Tolerance and acceptance of hepatic venous pressure gradient measurement in cirrhosis (CHESS1904): An international multicenter study

Author

Jun‐Hui Sun, He Zhao, Haijun Zhang, Lei Li, Necati Örmeci, Zi‐Niu Yu, Xun Li, Shuangxi Li, Xujun Yang, Huaping Wei, Xiaoliang Zhu, Zhengcong Zhang, Yajin Wang, Zhongwei Zhao, Jianting Mao, Qiaohong Wu, Xiaole Sun, Huiling Xiang, Kefeng Jia, Chao Yang, Wei Wu, Xiuqing Lin, Haixin Yao, Changzeng Zuo, Jitao Wang, Bo Zhang, Chunqing Zhang, Xiaoling Wu, Guangchuan Wang, Shengjuan Yao, Ruihang Wang, Li Zhou, Hui Huan, Qingli Tu, Xue Pu, Feng Zhang, Qin Yin, Linpeng Zhang, Ying Guo, Jian Wang, Kohei Kotani, Sawako Uchida‐Kobayashi, Norifumi Kawada, He Zhu, Li Li, Wei Wang, Guo Zhang, Lei Yu, Xudong Cui, Qingliang Zhu, Hailong Zhang, Xiaoli Hu, Rafael O. Ximenes, Adriano Gonçalves de Araújo, Giulliano Gardenghi, Yubao Zheng, Zebin Wu, Mingsheng Huang, Xiaoyong Chen, Jun Wu, Feng Xie, Yang Bo, Shengjuan Hu, Linke Ma, Xiao Li, and Xiaolong Qi

Subjects
design, hypertension, multicenter study, portal, pressure, prospective study, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Aim To determine the tolerance and acceptance of hepatic venous pressure gradient (HVPG) measurements in patients with liver cirrhosis. Methods This prospective international multicenter study included 271 patients with cirrhosis who were scheduled to undergo HVPG measurement between October 2019 and June 2020. Data related to the tolerance and acceptance of HVPG measurements were collected using descriptive questionnaires. Results HVPG measurements were technically successful in all 271 patients, with 141 (52.0%) undergoing HVPG measurement alone. The complication rate was 0.4%. Postoperative pain was significantly lower than preoperative expected pain (p

Published
2022
Full Text
View/download PDF

3. Functional magnetic resonance imaging-based assessment of terlipressin vs. octreotide on renal function in cirrhotic patients with acute variceal bleeding (CHESS1903): study protocol of a multicenter randomized controlled trial

Author

Chuxiao Shao, Mingming Deng, Jianjun Zheng, Yuan-Cheng Wang, Ming Xu, Jian Xu, Xinwen Yan, Jiansong Ji, Jun Ye, Shengjuan Yao, Xiaolong Qi, Fengmei Wang, Ruoyang Shao, Gao-Jun Teng, Aimin Liu, Xun Li, Huimin Zhao, Shenghong Ju, Xijun Gong, Jitao Wang, Tong Dang, Dengxiang Liu, Fengxiao Gao, Xingshun Qi, Yuqiang Mi, Chao Liu, Yunhong Wu, Liting Zhang, Junqiang Lei, Xiaorong Mao, Ping Li, and Ye Gu

Subjects
medicine.medical_specialty, Cirrhosis, business.industry, Acute kidney injury, Octreotide, Renal function, General Medicine, medicine.disease, Gastroenterology, law.invention, Study Protocol, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, Adverse effect, business, Terlipressin, medicine.drug
Abstract

Background: Acute variceal bleeding is one of the critical complications in patients with liver cirrhosis. Severe renal vasoconstriction in consequence of low peripheral vascular resistance triggers the reduction of glomerular filtration rate (GFR), and thus induces acute kidney injury (AKI)/hepato-renal syndrome (HRS). Terlipressin and octreotide have been used in the management of cirrhotic patients with variceal bleeding. Also, terlipressin has been recommended as the international first-line pharmacological therapy for the treatment of HRS. In addition, the use of renal functional magnetic resonance imaging (fMRI) has become increasingly prevalent in research and clinical applications. However, the renal function-protective effect of terlipressin and octreotide and the value of fMRI in monitoring renal function remains unclear in patients with cirrhosis undergoing acute variceal bleeding. Methods: This is a multicenter, randomized controlled trial (RCT). Participants will be 1:1 assigned randomly into either terlipressin or octreotide groups. Sixty participants with clinically and/or pathologically diagnosed cirrhosis and active gastroesophageal variceal bleeding (GVB) will be recruited in several sites in China. Participants will receive either the treatment of terlipressin or octreotide after assigned into each group. The primary end point for the trial is the renal function. The secondary end points are (I) renal perfusion; (II) renal blood oxygenation; (III) failure to control bleeding; (IV) intra-hospital rebleeding; (V) intra-hospital mortality; (VI) adverse events (AE); (VII) overall survival. Statistical analysis including multivariate Cox regression, Kaplan-Meier analysis with log-rank test, etc. will be conducted. Discussion: The study will provide new insight into the protection of renal function in the process of the treatment of variceal bleeding in patients with cirrhosis. Trial registration number: NCT04028323.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results